New York, NY (January 22nd, 2020) – LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1 clinical trial. LB-102 is a novel benzamide designed to be an improved version of amisulpride, a drug successfully used in Europe but unavailable in the United States. The ongoing study aims to evaluate the safety, tolerability, and pharmacokinetics / pharmacodynamics of LB-102 in healthy volunteers.
LB-102 was designed to mimic amisulpride’s binding affinity to the D2/D3 and 5HT7 receptors while improving brain permeability. Amisulpride is approved for the treatment of schizophrenia and is widely prescribed in over 50 countries, including the EU. In in vitro and in vivo preclinical assays, LB-102’s biophysicochemical properties, including PK, receptor binding, and behavioral studies, were equivalent or superior to amisulpride’s.